Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA advisory committee
Biotech
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of oncolytic virus RP1's effectiveness.
Darren Incorvaia
Jul 30, 2026 6:20pm
FDA adcomm shoots down Capricor's Duchenne cell therapy
Jul 29, 2026 6:06pm
FDA panel rejects AstraZeneca's novel oral SERD proposal
Apr 30, 2026 1:48pm
FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm
Apr 28, 2026 2:47pm
Fierce Pharma
FDA advisory committee to discuss action on unapproved peptides
Apr 15, 2026 5:15pm
FDA to end 9-month adcomm hiatus with review of AZ cancer drugs
Mar 6, 2026 11:16am